Cellular Therapy involves utilization of cells for treatment including haematopoietic stem cell transplantation (HSCT). HSCT may enable stem and progenitor cells to be engrafted, replacing the bone marrow of the recipient completely. Other examples include bone marrow-derived mesenchymal stromal cells, embryonic or induced pluripotent stem cells (iPs) and specific T-lymphocytic cell lines which can differentiate into a variety of cells. In the future this might also include the ex-vivo expansion of cord blood into red blood cells, platelets and their progenitors. Novel blood-derived therapeutics include platelet lysates, amniopatch and serum eye drops.
Current Leadership
Reinhard Henschler
Mickey Koh
Regional Director Europe (2024-2028)
Have you got a question for Mickey? Fill out the form below.
Christian Gabriel
Thierry Burnouf
Denese Marks
Denese Marks earned her PhD at the University of Technology, Sydney, followed by post-doctoral fellowships at the University of Vienna, the University of Melbourne and the Institute of Child Health at Great Ormond Street Hospital in London, as well as working in the biotechnology industry. Denese is the National Leader for Product Development at Australian Red Cross LifeBlood, where her research focuses on developing new blood products to meet patient needs, improving blood component processing and storage, platelet and red cell cryopreservation, pathogen inactivation and clinical trials of blood products. She is also an adjunct Associate Professor with the University of Sydney School of Medicine. Denese is a Section Editor for Vox Sanguinis, a scientific member of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and a member of the Executive Committee for the ISBT Cellular Therapies Working Party.Regional Director Western Pacific (2020-2024)
